Phase II study of cis-dichlorodiammineplatinum(II) in stage IVB Hodgkin's disease

M. P. Corder, T. E. Elliott, L. C. Maguire, J. T. Leimert, S. K. Panther, P. A. Lachenbruch

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

A broad phase II study of cis-dichlorodiammineplatinum(II) was conducted. Eight patients with stage IVB Hodgkin's disease were studied. Four of these patients attained an objective partial remission of 7-19+ weeks' duration. The usual time to the occurence of a ≥25% response was 1 week. This drug is active in far-advanced Hodgkin's disease with a projected lower limit of response rate from 19% to 21%.

Original languageEnglish (US)
Pages (from-to)763-766
Number of pages4
JournalCancer Treatment Reports
Volume63
Issue number5
StatePublished - 1979

Fingerprint Dive into the research topics of 'Phase II study of cis-dichlorodiammineplatinum(II) in stage IVB Hodgkin's disease'. Together they form a unique fingerprint.

  • Cite this

    Corder, M. P., Elliott, T. E., Maguire, L. C., Leimert, J. T., Panther, S. K., & Lachenbruch, P. A. (1979). Phase II study of cis-dichlorodiammineplatinum(II) in stage IVB Hodgkin's disease. Cancer Treatment Reports, 63(5), 763-766.